Identification of functional TFAP2A and SP1 binding sites in new TFAP2A-modulated genes by Orso, F et al.
Orso et al. BMC Genomics 2010, 11:355
http://www.biomedcentral.com/1471-2164/11/355
Open AccessR E S E A R C H  A R T I C L EResearch articleIdentification of functional TFAP2A and SP1 
binding sites in new TFAP2A-modulated genes
Francesca Orso†1,4, Davide Corà†2,4,5, Benedetta Ubezio1,6, Paolo Provero3, Michele Caselle†2,4 and Daniela Taverna*†1,4
Abstract
Background: Different approaches have been developed to dissect the interplay between transcription factors (TFs) 
and their cis-acting sequences on DNA in order to identify TF target genes. Here we used a combination of 
computational and experimental approaches to identify novel direct targets of TFAP2A, a key TF for a variety of 
physiological and pathological cellular processes. Gene expression profiles of HeLa cells either silenced for TFAP2A by 
RNA interference or not were previously compared and a set of differentially expressed genes was revealed.
Results: The regulatory regions of 494 TFAP2A-modulated genes were analyzed for the presence of TFAP2A binding 
sites, employing the canonical TFAP2A Positional Weight Matrix (PWM) reported in Jaspar http://jaspar.genereg.net/. 
264 genes containing at least 2 high score TFAP2A binding sites were identified, showing a central role in "Cellular 
Movement" and "Cellular Development". In an attempt to identify TFs that could cooperate with TFAP2A, a statistically 
significant enrichment for SP1 binding sites was found for TFAP2A-activated but not repressed genes. The direct 
binding of TFAP2A or SP1 to a random subset of TFAP2A-modulated genes was demonstrated by Chromatin 
ImmunoPrecipitation (ChIP) assay and the TFAP2A-driven regulation of DCBLD2/ESDN/CLCP1 gene studied in details.
Conclusions: We proved that our computational approaches applied to microarray selected genes are valid tools to 
identify functional TF binding sites in gene regulatory regions as confirmed by experimental validations. In addition, we 
demonstrated a fine-tuned regulation of DCBLD2/ESDN transcription by TFAP2A.
Background
The coordination of various complex biological functions
as well as the response to environmental and develop-
mental stimuli are governed by biochemical processes
that regulate gene activity. Transcription is the initial step
of gene expression and it involves a multitude of tran-
scription factors (TFs), their corresponding cis-acting ele-
ments on DNA, additional co-factors and the influence of
chromatin structure [1]. Functional TF binding sites
(TFBSs) can be identified in the genome by computa-
tional approaches or experimentally by Chromatin
ImmunoPrecipitation and hybridization on a genomic
microarray (ChIP on Chip) [2] or by high-throughput
selection procedures (SELEX) in which pools of random
DNA sequences are mixed with a TF and those that are
preferentially bound are recovered and sequenced [3,4].
However, an alternative and very promising approach
consists in combining in silico TFBS predictions in the
gene promoter regions and microarray analyses, compar-
ing gene expression of cells in which a TF is either over-
expressed or deleted [5-7]. Indeed, the analysis of regula-
tory sequences of putative co-regulated genes might be
useful in identifying common cis-regulatory elements
recognized by specific TFs [5]. The microarray assays
help to narrow down the number of genes to be analyzed,
focusing on those more likely to be regulated by the same
TFs, thus reducing the false positive and negative rates.
The Activator Protein-2 (TFAP2) family of transcrip-
tion factors includes five different yet closely related pro-
teins known as TFAP2A, TFAP2B, TFAP2C, TFAP2D
and TFAP2E [8-12] encoded by different genes. TFAP2
can positively or negatively regulate the promoter activity
of many pivotal genes involved in physiological or patho-
logical processes such as development, cell growth, dif-
ferentiation, apoptosis and tumorigenesis [12]. Among
the positively regulated genes are: CDKN1A, TGFA,
estrogen receptor, keratinocyte-specific genes, KIT, HIV
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Page 2 of 26KTF1, HTLVI, type IV collagenase, SV40 enhancer
region, human metallothionein gene IIa, ERBB2, IGFB5,
dopamine beta-hydroxylase. Examples of repressed genes
are: MCAM, CEBPA and MYC [12]. The crucial role of
the TFAP2 genes in regulating fundamental biological
processes is highlighted by the embryonic lethality of the
genetically modified Tcfap2a or Tcfap2b or Tcfap2 g mice
[12,13].
Every TFAP2 protein possesses a unique, highly con-
served helix-span-helix dimerization motif at the C-ter-
minal half of the protein, a central basic region and a less
conserved proline- and glutamine-rich domain at the
amino terminus [14]. The helix-span-helix motif and the
basic region mediate DNA binding and dimerization [15]
while the proline- and glutamine rich region is responsi-
ble for transcriptional transactivation. The TFAP2 pro-
teins are able to form hetero- as well as homo-dimers and
bind to GC-rich DNA sequences within regulatory
regions of their target genes, mediating both activation
and repression of gene transcription [12]. Functional
TFAP2 binding sites, such as 5'-GCCN3GGC-3' or 5'-
GCCN4GGC-3' or 5'-GCCN3/4GGG-3' have been iden-
tified [16]. However other well characterized binding
sites, such as 5'-CCCCAGGC-3' [17] or others [18],
which differ considerably from the previous sequences,
have also been found, indicating that TFAP2 binding sites
may represent promiscuous GC-rich elements varying
considerably in binding affinity. This makes the computa-
tional identification of TFAP2 binding sites not a trivial
process. A Positional Frequency Matrix (PFM) obtained
by multiple alignment algorithms, which leads to nucle-
otide scores indexed by letters and positions is often used
to localize degenerated cis-regulatory elements [19]. In
addition, given that TFAP2 isoforms are very similar in
their DNA binding domains, a specific sequence prefer-
ence between different TFAP2 proteins has not been
found, as demonstrated by an in vitro binding site selec-
tion with recombinant TFAP2A and TFAP2C proteins
[20].
Several molecular mechanisms control the TFAP2 pro-
tein activity and physical interactions with other proteins
play an important role. Among the most important
known TFAP2 interacting proteins, we can list DNA
binding factors such as YY1 [21]; YB1 [22]; TP53 [23];
SP1 [24]; MYC [25]; PAX6 [26]; RB1 [25]; CUX1 [27];
viral proteins such as SV40 large T antigen, 1 human T-
cell leukemia virus type 1 [28] and adenovirus E1A pro-
tein [29] as well as non-DNA-binding factors such as
WWOX [30]; GAS41 [31]; PARP1 [32]; APC [33]; CREB
[34]; CITED2 and 4 [35]; PC4 [36]; DEK [37] and YAP
[38].
We previously performed whole-genome microarray
analysis for HeLa cells either silenced for TFAP2A by
RNA interference or not and identified a set of differen-
tially expressed genes [39]. The regulatory regions (-900/
+100, considering the TSS as +1) of the genes that unam-
biguously mapped to known ENSEMBL IDs were ana-
lyzed for the presence of TFAP2A binding sites,
employing the canonical Positional Weight Matrix
(PWM) reported in Jaspar http://jaspar.genereg.net/. 264
genes containing at least 2 high score TFAP2A binding
sites were identified, several of which could be validated
by Chromatin ImmunoPrecipitation (ChIP) assays. Addi-
tionally, a detailed analysis of the TFAP2A-driven regula-
tion of the Discoidin, CUB and LCCL domain containing
2/Endothelial and Smooth muscle Derived Neuropilin
like/CUB, LCCL-homology, coagulation factor V/VIII
homology domains (DCBLD2/ESDN/CLCP1) gene was
performed. Finally we searched for TFs that might coop-
erate with TFAP2A in the transcriptional regulation of
genes containing at least 2 high score TFAP2A binding
sites and found SP1 as a potential candidate for TFAP2A
activated genes.
Results
Identification of TFAP2A binding sites in newly identified 
TFAP2A-modulated genes
In order to define TFAP2A binding sites in newly identi-
fied TFAP2A-modulated genes [39] we first assembled a
dataset of core promoter regions (-900/+100, considering
the TSS as +1) for all known human protein-coding genes
(21316) using the ENSEMBL database and searched for
TFAP2A binding sites employing the canonical TFAP2A
Positional Weight Matrix (PWM) MA0003 (Figure 1)
reported in the Jaspar database. Affinity scores were
assigned using standard log-likelihood ratios [40] and a
binding site defined as an oligonucleotide with log-likeli-
hood ratio higher than 66% of the maximum score possi-
bly associated to the PWM. After ranking the binding
sites by score, we used various thresholds (top-scoring
10%, 20% and 30% sites) to classify the genes containing
at least one or two high score TFAP2A binding sites
(Table 1). In the following we will mostly consider the
top-scoring 20% binding sites. We then focused on the set
of the differentially expressed genes identified by
microarray analysis [39], in which gene expression pro-
files of HeLa cells, either silenced for TFAP2A by RNA
interference or not were compared considering a Fold
Change (FC) > ± 1.5 and a p value (pv) < 0.01. For each of
them the longest available transcript was chosen (see
Additional file 1). Significant enrichment for TFAP2A
binding sites was found in the regulatory regions of these
genes compared with genome-wide abundance as calcu-
lated using an exact Fisher test, as shown in Table 1. In
the whole genome the genes containing at least one or
two high score TFAP2A binding sites were respectively
12686 and 8636 whereas, among TFAP2A-regulated
genes, 363 out of 494 genes (ENSEMBL) contained at
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494 (157 down- and 107 up-regulated) genes (ENSEMBL)
contained a minimum of two sites indicating an enrich-
ment for TFAP2A binding sites in the TFAP2A-regulated
genes (pv = 1.5E-05), see Table 1. The results for different
thresholds (top 10% and 30%) were similarly significant
and shown in Table 1. We ranked the genes according to
the number of TFAP2A binding sites present in their core
promoter regions (Table 2) and found that the majority of
the genes contained one or two TFAP2A binding site/s.
It's important to underline that already reported TFAP2A
target genes were identified in our analysis (see Addi-
tional file 1).
Functional classes enrichment for predicted TFAP2A target 
genes
To identify the functional pathways in which the potential
TFAP2A targets could be involved Gene Ontology (GO)
and network analyses were performed for the 264
TFAP2A-modulated genes containing at least two
TFAP2A high score binding sites using the Ingenuity
Pathway Analysis Systems. Two high score molecular net-
works were identified and in Figure 2A and 2B we show a
selection of these genes and their connections with
TFAP2A. The first network associated with Cellular
Movement (Figure 2A, score 38) and included 26 genes,
i.e. SLIT2 (slit homolog 2 -Drosophila); PDGFA (platelet-
derived growth factor alpha polypeptide); RAC1 and
RAC2 (ras-related C3 botulinum toxin substrate 1 and 2,
rho family, small GTP binding protein Rac1 and Rac2);
DCBLD2/ESDN (discoidin, CUB and LCCL domain con-
taining 2/Endothelial and Smooth muscle cell Derived
Neuropin-like molecule); ACTA2 (actin, alpha 2, smooth
muscle, aorta). The second network associated with Cel-
lular Development (Figure 2B, score 38) and included 24
genes, i.e. PPARG (peroxisome proliferator-activated
receptor gamma); MAPK1 (mitogen-activated protein
kinase 1); CXCL1 (chemokine, C-X-C motif, ligand 1 -
melanoma growth stimulating activity, alpha);
ADAMTS1 (metallopeptidase with thrombospondin type
1 motif, 1); AREG (amphiregulin); IL11 (interleukin 11).
Functional validation of potential TFAP2A-regulated genes
Potential TFAP2A binding was tested for 13 candidate
target genes containing at least one or two best 20%
TFAP2A binding sites by Chromatin Immuno Precipita-
tion (ChIP) assay (Figures 3 and 6): ADAMTS1 (ADAM
metallopeptidase with thrombospondin type 1 motif, 1);
CASP9 (caspase 9); CD59 (CD59 molecule, complement
regulatory protein); CXCL1 (chemokine ligand 1, mela-
noma growth stimulating activity alpha); EREG (Epiregu-
lin); DCBLD2/ESDN (endothelial and smooth muscle cell
derived neuropiline like molecule); FASTK (Fas-activated
serine/threonine kinase); GLO1 (glyoxalase I); KRT16
(keratin 16); KRT17 (keratin 17); PPARG (peroxisome
proliferator activated receptor gamma); SLIT2 (slit
Table 1: Identification of TFAP2A binding sites in the core promoter of candidate TFAP2A-modulated genes.
Minimum number of 
binding sites per gene
TFA2A binding site 
score threshold
Genome-wide TFAP2A-regulated genes p (Fisher test)
1 All sites 19402 468
best 30% (≥11.02) 14710 401 7.03E-08
best 20% (≥11.44) 12686 363 4.56E-09
best 10% (≥12.14) 9416 283 1.02E-07
2 All sites 17540 447
best 30% (≥11.02) 10959 322 1.03E-05
best 20% (≥11.44) 8636 264 1.53E-05
best 10% (≥12.14) 4955 155 2.0E-03
Number of genome-wide or candidate TFAP2A-modulated human protein-coding genes containing at least one or two high score TFAP2A 
binding sites defined at various score thresholds (10%, 20%, 30%) in their core promoters. By considering only high-scoring sites we obtained 
a significant enrichment in TFAP2A-modulated genes compared with total binding sites, as shown by the p-values in the last column (exact 
Fisher Test).
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Page 4 of 26Table 2: Distribution of genes containing TFAP2A binding sites.
Genes
Genome-wide TFAP2A-regulated
Minimum number of binding sites per gene best 20% (≥11.44) n° % n° %
1 12686 65.36 363 77.56
2 8636 44.50 264 56.41
3 5967 30.75 185 39.53
4 4131 21.30 133 28.42
5 2816 14.51 102 21.79
6 1948 10.04 72 15.38
7 1339 6.90 51 10.90
8 920 4.74 35 7.48
9 646 3.33 22 4.70
10 448 2.31 14 2.99
11 297 1.53 12 2.56
12 195 1.00 7 1.50
13 129 0.66 4 0.85
14 85 0.44 1 0.21
15 57 0.29 0 0
16 31 0.16 0 0
17 20 0.10 0 0
18 14 0.07 0 0
19 8 0.04 0 0
21 5 0.03 0 0
22 3 0.01 0 0
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Page 5 of 26homolog 2, Drosophila); TGFBI (Transforming Growth
Factor B-Induced). The ENSEMBL ID, microarray Fold
Change (FC) and TFAP2A binding sequences, scores and
positions for each of these genes is shown in Table 3.
ChIP analysis was performed on HeLa cells, that endoge-
nously express TFAP2A and as shown in Figure 3 and 6,
enrichment for TFAP2A was found on the promoter of
each gene compared with negative controls, suggesting in
vivo binding and direct regulation of these genes by
TFAP2A. Negative controls for ChIP analysis were per-
formed using genes in which low score or no TFAP2A
binding sites were identified such as PLCXD2 (pleckstrin
homology-like domain family B member 2) or IFI44
(interferon-induced protein 44). In fact, no enrichment
for TFAP2A was observed in the promoter of these two
genes compared with the negative IgG controls suggest-
ing that genes containing only low score or no TFAP2A
binding sites are not direct TFAP2A targets and their
TFAP2A-dependent modulation is indirect. ChIP analy-
sis for PPARG and PLCXD2 genes was also performed in
HepG2 cells that do not express TFAP2A and no enrich-
ment for TFAP2A was observed for any of the analyzed
sequences supporting the significance of the results
obtained in HeLa cells (Figure 3 and 6).
The DCBLD2/ESDN/CLCP1 promoter region is directly 
regulated by TFAP2A
DCBLD2/ESDN/CLCP1 (discoidin, CUB and LCCL
domain containing 2/Endothelial and Smooth muscle cell
Derived Neuropin-like molecule/CUB, LCCL-homology,
coagulation factor V/VIII homology domains protein)
turned out to be the most highly modulated (repressed)
gene in our microarray analysis on HeLa cells (FC + 5.7)
and to have an important role in cell migration [39]. For
these reasons we carried on a detailed computational
analysis of the DCBLD2/ESDN regulatory region,
extended to (-2185/+89 with respect to the TSS), and
found high enrichment of GC content and no TATA box
around the TSS, features which are common to the core
promoters of TFAP2A targets identified with our compu-
tational analysis. This sequence was analyzed to position
potential TFAP2A binding sites using the canonical
TFAP2A Positional Weight Matrix (PWM) as in Jaspar
database (see above). Three highly scored TFAP2A bind-
ing sites were identified in the region -360/+89. A sche-
matic representation of the 2.185 Kb DCBLD2/ESDN
promoter is shown in Figure 4A. This region was ampli-
fied from a BAC genomic clone (see Methods) and cloned
in a luciferase reporter vector generating the pGL3-
ESDN-WT (ESDNwt) construct. The effects of TFAP2A
on promoter activity were tested by performing reporter
assays in HeLa and MDA-MB-231 cell lines expressing,
respectively, medium and low levels of TFAP2A as
assessed by Western Blot (WB) analyses shown in Figure
4B and 4C. Both cell lines were transiently co-transfected
with either ESDNwt or its 5' deletant pGL3-ESDN-DEL3
(del3) starting at -950 or pGL3-Basic (basic) control
reporter vector and an expression plasmid for TFAP2A,
pSP(RSV)TFAP2A (TFAP2A) or its control empty vector
(EV) (Figure 4B and 4C). Alternatively HeLa cells (Figure
4B) were transfected with an expression vector for
TFAP2A silencing, pSUPER-TFAP2AshRNA2
(shTFAP2A), or with the empty pSUPER control vector
(shEV). In addition, cells were transfected with the
pRLTK vector for Renilla luciferase expression, to per-
form transfection efficiency normalization. TFAP2A
basal levels, overexpression or silencing were verified by
Western Blot (WB) analyses (Figure 4B and 4C) where
Glyceraldheyde-3-phosphate dehydrogenase (GAPDH)
was used as loading control. 3 fold higher activity was
observed for the ESDNwt reporter vector in MDA-MB-
231 cells compared with HeLa cells (compare Figure 4B
with 4C). The inhibitory function of TFAP2A on
DCBLD2/ESDN gene transcription was further sup-
ported when HeLa and MDA-MB-231 cells were co-
transfected with ESDNwt and TFAP2A (250 ng, other-
wise specified) with respectively 2 and 3.5 fold reduction
in luciferase activity (Figure 4B and 4C). This reduction
was inversely proportional to the TFAP2A levels in cells
(12.5 or 125 or 250 ng), as shown in Figure 4C for MDA-
MB-231 cells. Instead, TFAP2A silencing in HeLa cells
caused a 1.6 fold increase in reporter activity (Figure 4B).
All together these results strongly suggest a direct repres-
sive activity of TFAP2A on DCBLD2/ESDN promoter
and are in agreement with our previous microarray
results [39].
Specific role of the TFAP2A binding sites present in 
DCBLD2/ESDN promoter
A detailed functional analysis was performed for the
main TFAP2A binding site present in DCBLD2/ESDN
promoter by carrying out site-directed mutagenesis to
26 2 0.01 0 0
27 1 0.01 0 0
Distribution of genome-wide or TFAP2A-modulated genes based on absolute number of genes (or percentages, %) containing one or more 
high score (best 20%) TFAP2A binding sites in their core promoters.
Table 2: Distribution of genes containing TFAP2A binding sites. (Continued)
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Page 6 of 26obtain 7 bp deletions in the central portion of each
TFAP2A binding site in single or multiple combinations
to generate the constructs reported in Figure 5. Muta-
tions in the TFAP2A binding sites 1 or 2 or 3
(ESDNMUT1 or ESDNMUT2 or ESDNMUT3) pro-
duced statistically significant increased promoter activity
just like mutations for multiple TFAP2A binding sites 1,2
or 1,3, or 2,3 or 1,2,3 (ESDNMUT1; ESDNMUT1,2;
ESDNMUT1,3; ESDNMUT2,3; ESDNMUT1,2,3) as indi-
cated by the student's t tests: * pv < 0.05; ** pv < 0.01 sug-
Figure 1 Sequence logo and canonical Positional Weight Matrix (PWM) of TFAP2A. Logo (A) and frequencies (B) defining the TFAP2A PWM 
MA0003 are shown as provided by Jaspar database http://jaspar.genereg.net/.
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Figure 2 Ingenuity Pathway Analysis Systems for the genes containing at least 2 high score TFAP2A binding sites. Specific functional net-
works for the 264 genes containing at least 2 high score TFAP2A binding sites were obtained using Ingenuity Pathway Analysis Systems. A simplified 
representation of the two main molecular networks identified, "Cellular Movement" (A) and "Cellular Development" (B) is shown. Legend: Up- or 
down-regulated genes are shown in red or green respectively; continuous grey lines indicate direct interactions experimentally proven in literature; 
dashed grey lines represent potential indirect connections; continuous black lines represent direct connections demonstrated by our microarray and 
ChIP analyses; dashed black lines represent potential direct connections demonstrated by our microarray results [39]. Octagons indicate genes absent 
in the 264 gene dataset but related to it as indicated from the literature. Red lines indicate direct connections demonstrated by our microarray, ChIP 
and promoter analyses.
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Page 8 of 26Table 3: TFAP2A binding site sequences present in the regulatory regions of some TFAP2A- modulated genes.
Gene Symbol ENSEMBL ID Microarray FC TFAP2A binding 
sequence
TFAP2A binding 
score
Position
ESDN/DCBLD2 ENSG00000057019 5.7 GCCGCGGGG 12.74 -269
GCCCGCAGC 11.54 -10
PPARG ENSG00000132170 2.6 GCCTGAGGC 11.48 -851
GCCGGGGGC 12.82 -280
GCCGCGGGG 12.74 -176
GCCCCGCGG 11.77 -175
GCCGTGGGC 11.94 -134
GCCCGGCGC 11.85 +10
GCCCGCGGC 12.85 +42
EREG ENSG00000124882 2.5 CCCTCGGGC 12.75 -101
CXCL1 ENSG00000163739 2.4 GCCCGGGGG 13.46 -64
GCCCCCGGG 12.76 -63
GCCCGGAGC 12.14 -56
GCCGCAGGC 11.91 +13
CD59 ENSG00000085063 1.7 GCCCTGGGG 12.58 -336
GCCCCAGGG 12.55 -335
GCCGGGAGC 11.51 -37
GCCGGGGGG 12.83 +3
ADAMTS1 ENSG00000154734 1.7 GCCCGCAGC 11.54 -142
GCCGGGGGC 12.82 -107
SLIT2 ENSG00000145147 1.7 GCCGGGGGC 12.81 -679
GCCCCGAGG 12.06 -248
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Page 9 of 26CASP9 ENSG00000132906 -1.5 GCCCTGGGG 12.58 -734
GCCCCCAGG 11.45 -463
GCCCCCAGG 11.45 -370
GCCCGCAGG 11.55 -182
GCCCTGGGG 12.58 +4
GCCCCCAGG 11.45 +69
GCCCCGCGC 11.75 +2
TGFBI ENSG00000120708 -1.6 GCCCTGGGG 12.58 -899
GCCCCCAGC 11.44 -414
GCCCTGGGC 12.57 -212
GCCCTGGGC 12.57 +43
GLO1 ENSG00000124767 -2.0 GCCGCGGGC 12.72 -24
FASTK ENSG00000164896 -2.2 GCCCGGAGG 12.15 -856
GCCCCGAGC 12.04 -500
GCCCGGGGC 13.45 -413
GCCCCGGGG 13.36 -393
GCCCCCGGG 12.76 -391
GCCCTCGGC 11.97 -66
GCCCGGCGC 11.85 -59
GCCCGCGGG 12.86 -42
GCCGGGAGC 11.51 -2
KRT16 ENSG00000186832 -2.5 GCCCTCGGG 11.98 -860
GCCCCCGGG 12.76 -650
GCCTGAGGC 11.48 -502
Table 3: TFAP2A binding site sequences present in the regulatory regions of some TFAP2A- modulated genes. 
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Page 10 of 26gesting that each binding site plays a role in repressing
the promoter activity.
Identification of Transcription Factor Binding Sites (TFBSs) 
present in the promoter regions of TFAP2A-regulated 
genes by over-represented DNA oligonucleotides or 
oPOSSUM or MEME analysis
The properties of the core promoter region sequences of
the 264 best 20% TFAP2A-regulated genes were studied
by using three different approaches based on different
biological assumptions and statistical filters such as: 1)
short over-represented oligonucleotides; 2) oPOSSUM;
3) MEME.
1. Over-represented oligonucleotides
We performed a genome-wide characterization of the
previously described core promoters of human-protein-
coding genes, working on the statistical properties of
short (5 to 9 nt) DNA oligonucleotides (oligos) present in
these sequences. In particular, we identified sets of genes
sharing over-represented oligos in their promoter regions
according to a binomial model (see Methods for details).
We then characterized the evolutionary properties of
these oligos using a "conserved over-representation"
approach, an alignment-free methodology applied to
human-mouse comparison [41]. The resulting different
sets of genes were then compared with the up- and down-
TFAP2A-regulated gene datasets, described above and
the enrichment for oligos in TFAP2A-regulated genes
was assessed in the different sets of genes using an exact
Fisher test (pv < 0.05) as shown in Table 4. Results were
ranked according to the corresponding pv and the top 10
over-represented oligos are shown in Table 4. For some of
these oligos the over-representation is conserved (indi-
cated in Table 4 with an asterisk, *) suggesting an evolu-
tionarily conserved role for them. When possible, a
known TFBS consensus was then associated to each
oligo, using the list of TRANSFAC TFBS consensus
sequences reported in [42]. Interestingly, as shown in
Table 4, some of the most over-represented oligos found
for the TFAP2A-down-regulated genes correspond to the
SP1 consensus sequence (Fisher test: 7.76E-07; 38 target
genes). For the up-regulated genes we found many over-
represented oligos but we were not able to link them to
any known TF.
2. oPOSSUM
oPOSSUM [43] is able to evaluate the over-representa-
tion of known TFBS on human/mouse conserved
regions. We used this tool to analyze the sets of TFAP2A-
regulated genes setting the parameters indicated in
Methods. Results are reported in Table 5 for the up- and
down-regulated genes separately. A strong enrichment
was observed for SP1 (Fisher score: 2.19 10E-05; Z-score:
17.47; 95 target genes) and NHLH1 (Fisher score: 7.09 E-
GCCCCGAGG 12.06 -279
GCCCTCGGG 11.98 -277
KRT17 ENSG00000186831 -2.7 GCCCCGGGG 13.36 -525
GCCCCGGGG 13.36 -524
GCCCCCAGC 11.44 -203
GCCTGGGGG 12.30 +56
PLCXD2 ENSG00000144824 -1.5 CCCCCTTGGC 9.47* -878
GGCCAGGGC 9.04* -64
IFI44 ENSG00000137965 -1.9 - - -
For each ChIP-validated TFAP2A target gene or negative control (see figure 3 and 6) Gene Symbol, ENSEMBL IDs, TFAP2A binding site 
sequence, score and position (referring to the TSS as +1) are shown. ADAMTS1: ADAM metallopeptidase with thrombospondin type 1 motif, 
1; CASP9: caspase 9; CD59: CD59 molecule, complement regulatory protein; CXCL1: chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity alpha); DCLBD2/ESDN: Endothelial and smooth muscle cell derived neuropiline like molecule; EREG: Epiregulin; FASTK: 
fast kinase; GLO1: glyoxalase I; KRT16: keratin 16; KRT17: keratin 17; IFI44: interferon-induced protein 44; PLCXD2: pleckstrin homology-like 
domain family B member 2; PPARG: peroxisome proliferator activated receptor gamma; SLIT2: slit homolog 2 (Drosophila); TGFBI: 
Transforming Growth Factor Beta-Induced. * low score binding sites, used as negative controls.
Table 3: TFAP2A binding site sequences present in the regulatory regions of some TFAP2A- modulated genes. 
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Page 11 of 2605; Z-score: 14.76; 44 target genes) on down-regulated
genes. An enrichment for Pax5 (Fisher score: 3.31 E-03;
Z-score: 9.98; 12 target genes) and Cebpa (Fisher score:
6.67 E-03; Z-score: 8.20; 41 target genes) was observed for
the up-regulated genes even if the statistical relevance
was weaker then what observed for the down-regulated
genes.
3. MEME
MEME is a software for the ab-initio identification of rel-
evant motifs in a given set of sequences in which a motif
is a sequence pattern that occurs repeatedly in a group of
related DNA sequences [44]. The parameters used in our
analysis are indicated in Methods and the results
obtained are reported in Table 6: MEME regular expres-
Figure 3 In vivo Chomatin ImmunoPrecipitation (ChIP) analysis for putative TFAP2A binding sites on the core promoters of potential 
TFAP2A target genes. Pre-cleared chromatin from HeLa or HepG2 cells was immunoprecipitated with either non-specific IgG (IgG, negative control) 
or anti-RNA polymerase II or anti-acetylhistone H3 (positive controls: Positive Ctrl) or anti-TFAP2A (TFAP2A) antibodies. Immunoprecipitated DNA or 
non-immunoprecipitated chromatin samples (input) were amplified by PCR using primer pairs designed with the NCBI Primer Designing Tool (see 
Methods) across the TFAP2A putative binding sites. CD59: CD59 molecule, complement regulatory protein; CXCL1: chemokine (C-X-C motif) ligand 
1 (melanoma growth stimulating activity alpha); DCLBD2/ESDN: endothelial and smooth muscle cell derived neuropilin like molecule; EREG: epireg-
ulin; FASTK: fast kinase; GLO1: glyoxalase I; IFI44: interferon-induced protein 44; PLCXD2: pleckstrin homology-like domain family B member 2; PPARG: 
peroxisome proliferator activated receptor gamma; SLIT2: slit homolog 2 (Drosophila). C-, PCR negative control; FC, fold changes obtained from the 
microarray analysis [39]. Number (n°) of TFAP2A binding sites identified computationally. Three independent experiments were performed and a rep-
resentative one is shown here.
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Figure 4 Regulation of the DCBLD2/ESDN promoter by TFAP2A. (A) The genomic organization of the human DCBLD2/ESDN promoter (-2185/+89) 
is shown and the three highest score TFAP2A binding sites identified are framed and named 1 or 2 or 3. The Transcription Start Site (TSS) is considered 
+1. (B)(C) HeLa (B) and MDA-MB-231 (C) cells were transiently co-transfected with either pGL3-Basic (basic) or pGL3-ESDN-WT (ESDNWT) or pGL3-
ESDN-del3 (del3) vectors together with pSP(RSV)TFAP2A (TFAP2A) or TFAP2AshRNA2 (shTFAP2A) or their respective control empty vectors (EV or shEV) 
to obtain TFAP2A over-expression or down-modulation. pRLTK (Renilla luciferase) vector was transfected along to evaluate transfection efficiency and 
perform normalizations. Forty-eight hours later Firefly Luciferase activity was measured and normalized against Renilla Luciferase. Fold Changes were 
calculated referring to the pGL3-basic control vector and expressed as Relative Luciferase Units (RLUs). 250 ng of TFAP2A or shTFAP2A or EV or shEV 
were transfected unless specified differently. Three independent experiments were performed in triplicate and a representative one is shown here. 
The error bars indicate the Standard Errors (SE) of the triplicates. A student's t test was performed to evaluate if the experiments were statistically sig-
nificant. * pv < 0.05; ** pv < 0.01; *** pv < 0.001. TFAP2A levels were measured by Western Blot (WB) analysis. Glyceraldheyde-3-phosphate-dehydroge-
nase (GAPDH) expression was used for protein loading controls.
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Page 13 of 26sion motifs and the relative E-values for the most inter-
esting motifs are indicated. MEME results are not directly
associated to known TFBSs and to investigate whether
the resulting motifs could be recognized as known TFBSs
the same approach used previously for the oligo analysis
was used here [42]. For this identification, perfect match
between MEME regular expression and the IUPAC
equivalent was required, as shown in Table 6, and associ-
ation between motifs and known TFs was found in some
cases. Enrichment for SP1 was also found with this
method, in particular for down-regulated genes (E-value:
3.1E-085; 24 target genes).
Positioning of the SP1 binding sites in the promoter 
regions of TFAP2A-down-regulated genes and functional 
validation
After having observed an enrichment for SP1 binding
sites in the 157 TFAP2A-down-regulated genes with the
three methods mentioned above, we searched for SP1
sites in the promoter regions of these genes using the
same approach employed to recognize TFAP2A binding
sites: Jaspar, SP1 Positional Weight Matrix MA0079, cut
off on the best 20% score. 57 genes containing at least one
SP1 binding sites were identified and are listed in Table 7.
In the same table it is also indicated if these SP1 motifs
were identified with the over-represented oligo or oPOS-
SUM or MEME approach or not. SP1 binding sites were
found in: 2 common genes identified with the oligo analy-
sis and MEME; 12 genes common to oligo analysis and
oPOSSUM; 5 genes common to MEME and oPOSSUM;
the only common gene to the triple intersection was
OLFML2A. It is important to underline that SP1 sites did
not overlap with TFAP2A binding motifs (data not
shown).
Potential SP1 binding was tested for 4 candidate target
genes containing one or two best 20% SP1 and TFAP2A
binding sites by Chromatin Immuno Precipitation (ChIP)
assay, as indicated by Jaspar PWMs. See Figure 6. The 4
candidate genes were CASP9 (caspase 9); KRT16 (keratin
16); KRT17 (keratin 17) and TGFBI (Transforming
Growth Factor B-Induced). ChIP analysis was performed
on HeLa cells, using specific anti-SP1 and TFAP2A anti-
body. As shown in Figure 6, enrichment for SP1 together
with TFAP2A was found on the promoter of each gene
compared with negative controls, suggesting a functional
role for both cis-elements. Negative controls for ChIP
analysis were performed using genes where no high score
binding sites for either SP1 or TFAP2A were identified
Figure 5 Functional analysis of the TFAP2A binding sites present in the DCBLD2/ESDN promoter. HeLa cells were transiently transfected with 
700 ng of either pGL3-Basic (basic) or pGL3-ESDN-WT (ESDN-WT) or pGL3-ESDN-MUT1 (ESDN-MUT1), pGL3-ESDN-MUT2 (ESDN-MUT2), pGL3-ESDN-
MUT3 (ESDN-MUT3), pGL3-ESDN-MUT1,2 (ESDN-MUT1,2), pGL3-ESDN-MUT1,3 (ESDN-MUT1,3), pGL3-ESDN-MUT2,3 (ESDN-MUT2,3), pGL3-ESDN-
MUT1,2,3 (ESDN-MUT1,2,3) vectors. pRLTK (Renilla luciferase) vector was transfected as well to evaluate transfection efficiency and perform normal-
izations. Fold changes were calculated relative to the pGL3-Basic control vector and expressed as Relative Luciferase Units (RLU). Three independent 
experiments were performed in triplicate and a representative one is shown here. The error bars indicate the Standard Error (SE) of the replicates. * pv 
< 0.05; ** pv < 0.01. Wild type binding sites = white boxes; Mutated binding sites = black boxes.
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Table 4: Identification of transcription factor binding sites (TFBSs) present in TFAP2A- modulated genes by over-
represented DNA oligonucleotides.
TFAP2A-regulated 
genes
Over-represented 
oligo
TF Target 
genes
p (Fisher test)
DOWN n = 157 CGGGC* AP-2alpha, C-Rel, MYB, AMEF-2 22 1.20E-07
GAGCCGGC 27 1.48E-07
CCCGC* OLF-1, AP-2alpha, Sp-1,TCF-1(P),EGR 38 7.76E-07
CCCGGC* AP-2alpha, MTF-1 47 1.20E-06
CCCCGAGG* AP-2alpha 51 4.57E-06
CGGCA* AP-2alpha 57 7.08E-06
CCCATCCTA 64 1.17E-05
CGGCAGCC 65 1.51E-05
GCCCGC* AP-2alpha 66 2.45E-05
CGGGTGCTC 70 2.75E-05
UP n = 107 AAGCGCG* 6 8.32E-06
GGGGACTAA 11 1.62E-05
AGACGTCT 16 2.04E-05
AAACAACAG* 21 4.27E-05
ACCCACGCG* 26 5.13E-05
CGGGGTAGA 29 5.89E-05
CCTGTTTCG* 33 6.92E-05
CCGGAG 40 7.08E-05
ACGGGTTCT 42 7.59E-05
CCGGAGGC AP-2alpha 43 8.13E-05
For each TF its consensus binding site sequence, abbreviated name, number of target genes and statistical enrichment values (Fisher-score) 
are reported. * conserved over-represented oligo
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Page 15 of 26such as ADAMTS1 (ADAM metallopeptidase with
thrombospondin type 1 motif, 1) and PLCXD2 (pleck-
strin homology-like domain family B member 2). Enrich-
ment for TFAP2A but not for SP1 was found for
ADAMTS1 while no enrichment for both TFs was
observed for PLCXD2.
Discussion
The results presented in this work show how powerful an
in silico approach can be for the identification of func-
tional Transcription Factor Binding Sites (TFBSs), in par-
ticular when computational investigations are associated
with microarray analysis. In fact, while microarray analy-
sis is, by definition, not able to discriminate between
direct or indirect Transcription Factor (TF) gene expres-
sion modulation [45], the positioning of TFBSs on differ-
entially expressed genes allows the identification of genes
directly regulated by the TF of interest. By analyzing gene
expression profiles on HeLa cells either silenced for
TFAP2A by RNA interference or not [39] we were previ-
ously able to identify a subset of new TFAP2A regulated
genes on which it was possible to position high score
TFAP2A binding sites and find an enrichment of sites
compared with genome-wide [5,6]. The strength of our
computational approach was consolidated by experimen-
tal validations revealing TFAP2A binding to the high
score TFAP2A sites identified but not to portions of DNA
without TFAP2A binding sequences or containing only
low score sites.
A network analysis performed with Ingenuity Pathway
Analysis Systems for the TFAP2A-modulated genes con-
taining at least two high score TFAP2A binding sites
revealed "Cellular Movement" and "Cellular Develop-
ment" as the main networks confirming results previously
obtained in our and other laboratories. In fact, many
reports demonstrated that TFAP2A plays a major role in
development [12] and we recently showed a function for
TFAP2A in cell migration and/or invasion for tumor cells
[39] and neurons [46]. Genes involved in both biological
processes were previously identified however several new
ones have been discovered here. Among the already
known genes, PPARG, MAPK1, and VEGF [47] are pres-
ent in the networks confirming the validity of our analy-
sis.
The "Cellular Movement" network includes genes with
specific biological functions and some examples are listed
here. SLIT2 (slit homolog 2 -Drosophila) is involved in
induction of negative chemotaxis in neuronal cells, glial
cell migration, motor axon guidance and nervous system
development [48]. PDGFs (platelet-derived growth fac-
tors) are known to regulate cell proliferation as well as
migration for mesenchymal or endothelial cells [49].
Table 5: Identification of transcription factor binding sites (TFBSs) present in TFAP2A- modulated genes by opossum.
TFAP2A-regulated genes OPOSSUM matrix (Jaspar CORE) TF Target genes p (Fisher test) Z-score
DOWN n = 157 MA0079 SP1 95 2.19E-05 17.47
MA0048 NHLH1 44 7.09E-05 14.76
MA0006 Arnt-Ahr 99 3.21E-02 14.25
MA0056 MZF1_1-4 119 4.44E-02 11.27
MA0018 CREB1 45 9.48E-03 10.63
UP n = 107 MA0014 Pax5 12 3.31E-03 9.98
MA0102 Cebpa 41 6.67E-03 8.20
MA0042 FOXI1 35 2.12E-01 8.00
MA0135 Lhx3 32 2.11E-01 7.74
MA0047 Foxa2 35 1.93E-01 7.73
For each TF its Positional Weight Matrix (PWM) numbers, abbreviated name, number of target genes and statistical enrichment values (Z-
score, Fisher-score) are reported.
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Page 16 of 26Table 6: Identification of transcription factor binding sites (TFBSs) present in TFAP2A- modulated genes by MEME 
analysis.
TFAP2A-regulated 
genes
MEME regular expression TF Target genes MEME E-value
DOWN n = 157 [GA]CCTGTA[AG]TCCCAGC[TA][CA][CT]T[TC] PITX2, CRX 26 9.1E-162
AT[CT]CTCC[TC][GA]CCTC[AG]G 34 2.6E-058
T[CG][CG]A[GC][TA]CCAGCCTGG[GC]C[AG]AC 29 4.3E-104
AGG[TC]TGCAGTGAGC[CT]G[AT]GAT Sp-1, AP-2apha, MAZ, TFII-I 24 3.1E-085
GG[GA]GG[CA]GGGG[CGA][GC]GG[GA][GAC]G[GAC]GG 38 1.7E-056
GTGAGCCAC[CT][GA]CGCCCGGC[CT] 21 2.0E-049
UP n = 107 CTCCC[AG]A[AG][GT][TA]GCTGGGA[TC]TA MYOD, PITX2, CRX 20 2.1E-126
GT[CT]TC[AG]C[TC][AC]TGT[TC][GA][CG]CCAGG YY1, AP-2alpha 22 1.5E-082
G[GC]GGCGG[GC]G[GC][CG]GG[GC]GG[CG]GG[GC] Sp-1, AP-2alpha 35 9.7E-062
[GT]TGTGTGTG[TC]G[TC][GA][TC]GTGTG[TG] MYC 9 3.2E-016
G[GC][TC]TCAAG[CT]GAT[TC]CTCC[TC]GC NKX2-5 16 1.5E-049
CAGG[CT]G[TC]G[AC]GCCACC[GA]C[GA]CC AREB6, AML1 19 7.7E-067
ATCT[CT][GA]GCTCACTGCA[AG]CCT 16 9.8E-048
TGGTCTCGA[TA]CTCCTGACCT T3R, ER 12 8.0E-032
For each TF its consensus binding site sequence, abbreviated name, number of target genes and statistical enrichment values (E-value) are 
reported.
Interestingly, in vascular cells PDGFBB is known to up-
regulate DCBLD2/ESDN (discoidin, CUB and LCCL
domain containing 2/Endothelial and Smooth muscle cell
Derived Neuropin-like molecule), the most TFAP2A-
modulated gene in our microarray analysis. PDGFBB is
also known to be related to another TFAP2A-modulated
gene, ACTA2 (actin, alpha 2, smooth muscle, aorta),
which codes for a protein belonging to the actin family
that plays a role in cell motility, structure and integrity
and regulates blood pressure via vascular and smooth
muscle contraction [50]. RAC1 and RAC2 (ras-related C3
botulinum toxin substrate 1 and 2) are small GTPases
belonging to the RAS superfamily and regulate a variety
of cellular events, including growth control, cytoskeletal
reorganization and protein kinase activation [51]. PDGF
and RAC1 are connected with each other since it was
demonstrated that all RAC1-related GTPases expressed
in mouse primary fibroblasts, Cdc42, Rac1, and RhoG,
are required for efficient migration following PDGF stim-
ulation [52].
Some of the genes included in Cellular Development
network are: PPARs (peroxisome proliferator-activated
receptors) form heterodimers with retinoid X receptors
(RXRs) and regulate the transcription of various genes.
Three subtypes of PPARs are known: PPARA, PPARD and
PPARG. The last one regulates adipocyte differentiation
and is involved in the pathology of numerous diseases
including obesity, diabetes, atherosclerosis and cancer
[53]. MAPK1 (mitogen-activated protein kinase 1) is a
member of the MAP kinase family and it is involved in
cellular proliferation, differentiation, transcription regu-
lation and development [54]. CXCL1 (chemokine, C-X-C
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Page 17 of 26Table 7: Summary of TFAP2A-down-modulated genes containing SP1 binding sites in their promoters
Down-modulated genes containing SP-1 binding sites
ENSEMBL ID Gene symbol Microarray FC Oligo oPOSSUM MEME
ENSG00000092871 RFFL -1.5 - - -
ENSG00000 SLCO4 -1.5 - - -
ENSG00000 C16or -1.5 - + -
ENSG00000 CDK6 -1.5 - + -
ENSG00000 GCN5L -1.5 - + -
ENSG00000 ATP8B -1.5 - - -
ENSG00000 CASP9 -1.5 + - -
ENSG00000 SPOCK -1.5 + + -
ENSG00000 FBN1 -1.5 - + -
ENSG00000 SMAD3 -1.5 + + -
ENSG00000 PHLDA -1.5 - + -
ENSG00000 DALRD -1.5 + + -
ENSG00000 GPRC5 -1.6 - - +
ENSG00000 KIAA1 -1.6 - - -
ENSG00000 COL12 -1.6 - + -
ENSG00000 TGFBI -1.6 - - -
ENSG00000 RDH10 -1.6 + + -
ENSG00000 MESP1 -1.6 - - -
ENSG00000 OPLAH -1.6 + + -
ENSG00000 ST4S6 -1.6 - + +
ENSG00000 BCOR -1.6 + + -
ENSG00000 RPS27 -1.6 - + +
ENSG00000 SLC25 -1.6 + - -
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Page 18 of 26ENSG00000 PDGFA -1.6 + + -
ENSG00000 DNMT3 -1.7 - + -
ENSG00000 EPB41 -1.7 + + -
ENSG00000 CDKN1 -1.7 + + -
ENSG00000 TMEM1 -1.7 - + -
ENSG00000 RNF38 -1.7 - - -
ENSG00000 SLC27 -1.7 + - -
ENSG00000 SLC43 -1.7 + + -
ENSG00000 DPYSL -1.8 - + -
ENSG00000 SLC7A -1.8 - - -
ENSG00000 PXDN -1.8 - - -
ENSG00000 COL5A -1.8 + + -
ENSG00000 SECTM -1.8 + - -
ENSG00000 GLS -1.9 - + -
ENSG00000 ENAH -1.9 - + -
ENSG00000 FTH1 -1.9 - - -
ENSG00000 SYNGR -2.0 - + +
ENSG00000 TXNIP -2.0 - + -
ENSG00000 LOXL2 -2.0 - - -
ENSG00000 STX6 -2.0 - + +
ENSG00000 RAB15 -2.0 + - -
ENSG00000 COX6B -2.0 - - -
ENSG00000 OLFML -2.0 + + +
ENSG00000 PAG1 -2.1 - + -
Table 7: Summary of TFAP2A-down-modulated genes containing SP1 binding sites in their promoters (Continued)
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Page 19 of 26motif, ligand 1 - melanoma growth stimulating activity,
alpha) belongs to the Chemokine family, a group of small,
structurally related molecules that regulate cell traffick-
ing of various types of leukocytes via the interaction with
a subset of 7-transmembrane, G protein-coupled recep-
tors [55]. In addition, CXCL1 is known to play a major
role in inflammation, angiogenesis, tumorigenesis and
wound healing [56]. ADAMTS1 (a disintegrin-like and
metalloprotease with thrombospondin type 1 motif, 1)
gene encodes for a member of the ADAMTS protein fam-
ily that has anti-angiogenic activity and the expression of
this gene may be associated with various inflammatory
processes as well as development of cancer and cachexia
[57]. The protein encoded by the AREG (amphiregulin)
gene is a member of the epidermal growth factor (EGF)
family involved in cell growth stimulation of astrocytes,
Schwann cells, fibroblasts and epithelial cells by interact-
ing with EGF receptor [58]. IL11 (interleukin 11) encodes
for a cytokine which stimulates the T-cell-dependent
development of immunoglobulin-producing B cells and
potentiates proliferation of hematopoietic stem cells and
megakaryocyte progenitors [59].
Since it is well known that TFAP2A cooperates with
other transcription factors (TFs) to regulate transcrip-
tion, three different methods, over-represented oligonu-
cleotides, oPOSSUM and MEME, were used to identify
TF which could possibly work in cooperation with
TFAP2A to regulate the 264 genes containing the best
score TFAP2A binding sites. Remarkably a common
enrichment for SP1 binding sites was found in genes con-
taining at least one or two high score TFAP2A binding
sites and transcriptionally activated by TFAP2A but not
in the repressed ones. SP1 is known to cooperate with
TFAP2A in transcription [60,61], however here we
underline the importance of SP1 specifically in TFAP2A
gene activation, but not in transcriptional repression and
localize SP1 binding sites to DNA nucleotide sequences
distinct from TFAP2A binding sites, although, from our
experiments, we cannot exclude the possible physical
interaction between TFAP2A and SP1.
Among the ChIP validated genes, the gene encoding for
Discoidin, CUB and LCCL domain containing 2/
Endothelial and Smooth muscle Derived Neuropilin like
(DCBLD2/ESDN) resulted the most modulated in our
microarray analysis with a (FC + 5.7). This is one of the
reasons why we decided to investigate its TFAP2A-
dependent transcription in detail together with its inter-
esting functions. Its protein structure resembles that of
neuropilins, transmembrane proteins which are promis-
cuous for ligands and co-receptors. DCBLD2/ESDN is
ubiquitously expressed but linked to metastasis forma-
tion since it has been cloned and found to be significantly
up-regulated from highly metastatic lung cancer cells
[62]. Various functional studies link DCBLD2/ESDN to
ENSG00000 SESN1 -2.1 - + -
ENSG00000 ACTA2 -2.1 - - -
ENSG00000 ANXA8 -2.2 - - -
ENSG00000 ZFAND -2.3 - + -
ENSG00000 KRT16 -2.5 - + -
ENSG00000 JMJD3 -2.6 - + -
ENSG00000 PLSCR -2.7 + - +
ENSG00000 USP18 -2.7 - - +
ENSG00000 KRT17 -2.7 - - -
ENSG00000127129 EDN2 -3.2 - + -
A search for SP1 Transcription Factor Binding Sites (TFBS) was performed on the promoter regions (-900/+100) of 157 TFAP2A-down-
modulated genes [39], mapped in ENSEMBL, containing at least one or two best 20% TFAP2A binding sites (see Table 1) using the SP1 
Positional Weight Matrix (PWM) provided by Jaspar. 57 genes containing SP1 TFBS were identified. The outcome obtained with the Oligo, 
oPOSSUM and MEME analyses are also indicated (see Table 4, 5, 6).
Table 7: Summary of TFAP2A-down-modulated genes containing SP1 binding sites in their promoters (Continued)
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Page 20 of 26tumor progression but a specific role in tumor promotion
or repression has not been defined yet [63,64]. DCBLD2/
ESDN expression was analyzed in our (unpublished data)
and other laboratories [63,65] in melanoma and breast
cell lines and found to be expressed only in highly meta-
static cells but not in their related poorly malignant vari-
ants suggesting a positive role for DCBLD2/ESDN in
tumor progression. DCBLD2/ESDN was also shown to be
part of an invasive breast cancer gene signature [66].
However in HeLa cells, used for our microarray analysis,
we demonstrated that TFAP2A regulates tumor cell
motility and invasion, at least partially, via DCBLD2/
ESDN in a negative manner [39]. Here TFAP2A down-
modulation prompted DCBLD2/ESDN up-regulation,
suggesting a possible direct repressive effect of DCBLD2/
ESDN transcription by TFAP2A. In our present investiga-
tion, overexpression of TFAP2A in cells expressing low or
high levels of TFAP2A, respectively MDA-MD-231 and
HeLa cells, led to decreased DCBLD2/ESDN promoter
activity although in MDA-MB-231 cells DCBLD2/ESDN
promoter activity was higher in comparison with HeLa
cells. Accordingly TFAP2A silencing induced higher
DCBLD2/ESDN promoter activity. Importantly, the nega-
tive effect of TFAP2A on DCBLD2/ESDN promoter was
dose-dependent since when MDA-MB-231 cells were
transfected with increasing levels of the TFAP2A-expres-
sion vector, a proportional down-regulation of transcrip-
tion was observed. All together, these findings strongly
suggest a direct repressive activity of TFAP2A on
DCBLD2/ESDN promoter and are in agreement with our
microarray results [39]. For these reasons we made the
hypothesis that if TFAP2A represses DCBLD2/ESDN
transcription, inverse expression profiles should exist for
the two genes and therefore we used an on-line expres-
sion atlas for RNA expressions in tumors http://
biogps.gnf.org. In some case high DCBLD2/ESDN
expression coincided with very low levels of TFAP2A in
tumor cells, while in other cases DCBLD2/ESDN high or
low expression co-existed with high TFAP2A expression.
In addition, for many tumors both genes showed compa-
rable TFAP2A low or medium RNA levels. Since it is
known that TFAP2 activity can be modulated by a wide
range of interacting proteins [12], it is conceivable that
differential expression and functional roles of TFAP2A
co-factors may account for distinct effects on DCBLD2/
ESDN gene transcription. Moreover, the presence of
Figure 6 In vivo Chomatin ImmunoPrecipitation (ChIP) analysis for putative SP1 binding sites on the core promoters of TFAP2A target 
genes. Pre-cleared chromatin from HeLa cells was immunoprecipitated with either non-specific IgGs (IgG, negative control) or anti-RNA polymerase 
II or anti-acetylhistone H3 (positive controls: Positive Ctrl) or anti-SP1 (SP1) or anti-TFAP2A (TFAP2A) antibodies (Ab). Immunoprecipitated DNA or non-
immunoprecipitated chromatin samples (Input) were amplified by PCR using primer pairs designed with the NCBI Primer Designing Tool (see Meth-
ods) across the TFAP2A or the SP1 putative binding sites. ADAMTS1: ADAM metallopeptidase with thrombospondin type 1 motif, 1; CASP9: caspase 
9; KRT16: keratin 16; KRT17: keratin 17; PLCXD2: pleckstrin homology-like domain family B member 2; TGFBI: Transforming Growth Factor Beta-In-
duced. The number (n°) of computationally predicted high score TFAP2A or SP1 binding sites are indicated. C-, PCR negative control; FC, fold changes 
obtained from the microarray analysis [39]. Three independent experiments were performed and a representative one is shown here.
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Page 21 of 26other TFAP2 isoforms and the relative ratios with one
another may be crucial here. On the other hand, in many
cases, both TFAP2A and DCBLD2/ESDN genes might
not be expressed. Finally, it is important to keep in mind
that RNA levels do not always correspond to actual pro-
tein levels or activity. For instance, TFAP2 proteins are
known to be modified post-translationally by phosphory-
lation, sumoylation and redox status, which may affect
their activity and cellular localization [12].
Three high and several low score TFAP2A binding sites
were identified in the promoter region of the DCBLD2/
ESDN gene by computational analysis however we only
investigated the functional role and contribution of the
main TFAP2A binding sequences. By doing so we
observed that each TFAP2A site was essential for repres-
sion of DCBLD2/ESDN transcription, in fact the inactiva-
tion of one or two or three site/s equally affected
promoter activity in luciferase assays. These experimen-
tal validations, confirm once again, that our computa-
tional analyses represent a powerful tool for the
identification of TF regulatory targets by predicting pre-
cisely their cis-elements [19]. To better understand the
repressive effect of TFAP2A on DCBLD2/ESDN tran-
scription, the interaction of TFAP2A with other co-fac-
tors will be studied in the future. A better comprehension
of the TFAP2A-driven regulation of the DCBLD2/ESDN
gene should provide novel and useful insights on mecha-
nisms of tumor progression and metastasis formation.
Conclusions
Our study was essential for: 1) identifying functional
TFAP2A binding sites in novel TFAP2A-regulated genes;
2) defining "Cellular Movement" and "Cellular Develop-
ment" as the main networks in which the TFAP2A target
genes are involved; 3) associate SP1 to TFAP2A gene
transcription activation but not repression; 4) dissecting
the TFAP2A-driven regulation of DCBLD2/ESDN, an
important player of tumor progression.
Methods
Definition of promoter sequences and TFAP2A binding site 
identification genome-wide
Whole-genome human protein-coding gene sequences
and annotations were downloaded from the ENSEMBL
database, version 46, [67]. Only the longest transcript was
considered for each gene and the promoter region
defined as 900 bps upstream and 100 bps downstream of
the Transcriptional Start Site (TSS), +900/-100 [68]. Each
promoter sequence was analyzed using the canonical
TFAP2A Position Weight Matrix (PWM) MA0003
reported in Jaspar database http://jaspar.genereg.net/
which consists of a 9 nucleotide GC-rich sequence. Affin-
ity scores were assigned to each TFAP2A binding site
using a standard log-likelihood ratio (LLR) scoring func-
tion with intergenic background frequencies. All sites
with score exceeding 66% of the maximum possible score
for the PWM were initially selected, then ranked by
score. We considered the top ranking sites (the thresholds
used were 10%, 20% and 30%) to identify genes carrying
at least two high score sites in their regulatory region.
The software described in [69] was used to rank the sites.
Identification of TFAP2A potential co-factors in the (-900/
+100) promoter regions using three different approaches
1) Over-represented and Conserved Oligonucleotides (Table 
4)
We first classified human and mouse genes in two catego-
ries (CG-rich and CG-poor) by analyzing the CG content
of their promoters using the median CG content of the
whole dataset as threshold. The two categories of genes
were then independently searched for over-represented 5
to 9 bps-long oligonucleotides (oligos) where the over-
representation was assessed using a binomial model [70]
and the overall frequency f(w) of each oligo w was com-
puted as:
where N(w) is the number of times that w occurs in the
entire collection of sequences and .
Instead ng(w) is the number of occurrences of w in the
promoter region of each gene g. The statistical signifi-
cance of over-representation was determined using the
binomial P-value:
where
is the total number of oligos of the same length as w
that can be found in the promoter region of g. Self-over-
lapping matches of the same oligo were discarded and
motifs were counted on both DNA strands. For each oligo
w we defined the set S(w) of the genes whose promoter
shows overrepresentation of w (Pg(w) < 0.01)
An oligo (w) was defined "conserved over-represented"
if the sets of genes Shuman(w) and Smouse(w) contained a sig-
nificantly larger number of orthologous genes than
expected by chance. Pairs of human-mouse orthologous
f(w) =
N(w)
N
N = N(w)
w
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Page 22 of 26genes were obtained from ENSEMBL. In order to obtain
one-to-one orthology relationships, only orthologous
genes defined as Unique Blast Reciprocal Hit were con-
sidered. The significance of the overlap between
Shuman(w) and Smouse(w) was determined with the exact
Fisher test, and multiple testing taken into account by
computing the False Discovery Rate (FDR) with the
method of Benjamini and Yekutiely [71]. For further anal-
ysis we retained the oligos with FDR < 0.1. Additional
details on this procedure can be found in [41,72]. In order
to identify possible TFAP2A co-factors a direct compari-
son of the over-represented oligo sequences with the
known consensus sequences for vertebrate Transciption
Factors (TFs) [42] was performed and the association
between motifs and TFs was accepted only if the over-
represented oligo fully overlapped (according to the
IUPAC alphabet).
2) oPOSSUM (Table 5)
The oPOSSUM program [43] was used to identify Tran-
scription Factor Binding Sites (TFBS) recognized by
potential TFAP2A co-factors considering 60% sequence
conservation between human and mouse as a minimum
requirement. With this approach the regulatory region
explored coincided with the smallest cut off we could
choose (-2000/0) even if it included additional upstream
bps compared with the over-represented oligo (see
above) and MEME analyses (see below). The other
parameters were left unchanged. A Fisher's exact test
with a pv < 0.05 was performed here to identify the highly
enriched TFBS [43].
3) MEME (Table 6)
The MEME program [44] was used to identify TFAP2A
potential co-factors considering 20 bps as the maximum
length of any motif (to fit the standard size of a typical
TFBS) and searching for motifs in both DNA strands. To
assess whether the motifs obtained by MEME may be
associated to any known TFBSs, each motif was associ-
ated to a putative TF based on [42].
Localization of SP1 TFBS in the (-900/+100) promoter 
regions
Using the three approaches mentioned above it was pos-
sible to identify an enrichment for SP1 TFBS in the pro-
moter regions of 157 TFAP2A-down-modulated genes
mapped in ENSEMBL containing at least two high-score
TFAP2A binding sites (see Table 1). In order to position
the SP1 TFBS an additional analysis using the JASPAR
PWM for SP1 (MA0079) was performed on the (-900/
+100) promoter regions of this group of down-regulated
genes, as described for TFAP2 (see above).
Cell lines, Antibodies and DNA constructs
The following human cell lines were used; their origins
and general properties, as illustrated by American Type
Culture Collection (ATCC, Manassas, VA, USA), are as
follows: HeLa: cervix adenocarcinoma (AC), HPV-18
positive; MDA-MB-231: breast AC, pleural effusion;
HepG2 (Human Caucasian hepatocyte carcinoma). Each
cell line was grown as suggested by ATCC. Primary anti-
bodies used were anti-: TFAP2A mAb 3B5 or TFAP2A
pAb C-18 or GAPDH pAb V-18 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) or SP1 pAb (Active Motif, Carlsbad,
CA) or acetylated-H3 histone pAb (Upstate Biotechnol-
ogy, Lake Placid, NY, U.S.A.). Secondary antibodies used
were: goat anti-mouse or anti-rabbit IgG HRP-conju-
gated, donkey anti-goat IgG HRP-conjugated (Santa Cruz
Biotechnology, Santa Cruz, CA); pSP(RSV)TFAP2A and
pSP(RSV)-empty expression vectors, a gift from Dr. H.
Hurst [73,74] were respectively used to overexpress
human TFAP2A in cells and as empty vector control.
TFAP2AshRNA2 [39] and pSUPER.retro.puro vector
(OligoEngine, Seattle, WA, USA) were respectively used
to down-modulate human TFAP2A in cells and as empty
vector control.
Molecular cloning of the human Endothelial and Smooth 
muscle Derived Neuropilin like (DCBLD2/ESDN/CLCP1) 
promoter
The upstream regulatory region of the DCBLD2/ESDN/
CLCP1 (discoidin, CUB and LCCL domain containing 2/
Endothelial and Smooth muscle cell Derived Neuropin-
like molecule/CUB, LCCL-homology, coagulation factor
V/VIII homology domains protein) gene was identified
using the National Center for Biotechnology Information
(NCBI) gene bank database (accession number
NM_080927). A BAC genomic clone
RZPDB737B122156D was purchased from imaGenes
(imaGenes GmbH, Berlin, Germany) and a 2274 bps frag-
ment encompassing the putative DCBLD2/ESDN pro-
moter region was amplified by PCR, using Takara (Bio
Inc., Shiga, Japan) reagents. A final 50 μL volume con-
tained: 2.5 U Takara LA Taq enzyme, 1 × PCR Buffer, 400
μM dNTPs, 2.5 mM MgCl2, 1 μM forward and reverse
primers and 0.1 μg of DNA. The following primers con-
taining KpnI and BglII restriction sites at the 5' ends were
used: FW: 5'-GGGGTACCCCCTGGCTGATTG-
GGGTTTTTA-3'; RV: 5'-GAAGATCTTCGCG-
GAGCTAAGGAACGTG-3'. A negative control without
plasmid was always added. 3'-overhang As were added by
a post-incubation with Taq polymerase (Invitrogen Life
Technologies, Carlsband, CA) then the fragment was
cloned into the pCR®2.1-TOPO vector using the TOPO
TA cloning system (Invitrogen Life Technologies, Carls-
band, CA). After sequencing, the fragment was excised
by KpnI and BglII digestion and subcloned into pGL3-
Basic Luciferase reporter vector (Promega, Madison, WI)
giving rise to the pGL3-ESDN-WT reporter construct (-
2185; +92). A 5'deletion construct was generated by
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Page 23 of 26digesting pGL3-ESDN-WT vector with KpnI-BalI restric-
tion enzymes, followed by Klenow end-filling reactions
(where necessary) and self-recircularization by Invitro-
gen ligase and named: pGL-ESDN-DEL3 (-950; +92).
QuickChange™ Site-Directed Mutagenesis Kit (Strata-
gene, La Jolla, CA) was used to generate 7 bp-deletions in
the central portion of every single TFAP2A binding site in
single or multiple combinations and pGL3-ESDN-MUT1,
pGL3-ESDN-MUT2, pGL3-ESDN-MUT3, pGL3-ESDN-
MUT1,2, pGL3-ESDN-MUT1,3, pGL3-ESDN-MUT2,3,
pGL3-ESDN-MUT1,2,3 reporter vectors were obtained.
Mutagenic primer sequences are listed in Additional file
2.
Chromatin ImmunoPrecipitation (ChIP) assays
ChIP was performed using the Magna ChIP™ G kit (Milli-
pore, Billerica, MA) reagents and protocols. Briefly, chro-
matin was prepared from HeLa or HepG2 cells at ~80-
90%. Cells were crosslinked with 1% formaldehyde
(Sigma Aldrich, St Louis, MO) for 10' at 37°C. Chromatin
shearing was obtained by digesting the DNA with an
enzymatic shearing cocktail (200 U/ml) for 10' at 37°C.
Chromatin was pre-cleared with Protein G beads, to
reduce non-specific background. Pre-cleared chromatin
was immunoprecipitated overnight using 2 μg of specific
antibodies. In addition, chromatin aliquots were precipi-
tated with either non-specific IgGs or with anti-RNA
polymerase II or anti-acetyl-histone H3 antibody, used
respectively as negative and positive controls. Immuno-
precipitated chromatin was collected by adding protein G
beads to the tubes and the beads were washed with ChIP-
IT™ Washing Buffers supplemented with protease inhibi-
tors. Immunoprecipitated DNA was collected and after
reversing the cross-links, DNA was purified by using the
QIAquick® PCR Purification Kit mini spin-columns (QIA-
GEN, Stanford CA), according to manufacturer's instruc-
tions. The eluted immunoprecipitated DNA was
analyzed by PCR, together with a non-immunoprecipi-
tated chromatin sample (input). Polymerase chain reac-
tion (PCR) was performed using Taq DNA Polymerase
(Invitrogen Life Technologies, Carlsband, CA) using 1 ×
PCR Buffer without MgCl2, 0.2 mM dNTPs, 1.5 mM
MgCl2, 0.5 μM forward and reverse primers, 0.625 U Taq
DNA Polymerase and 10 μL of precipitated DNA. The
annealing temperature and the number of cycles were
specific for each primer pair. The different primer pairs
were designed using the NCBI Primer designing tool and
primer sequences as well as PCR experimental conditions
are added in Additional file 2. To verify the quality of our
ChIP reactions, primers to the GAPDH promoter were
used as positive controls.
Transient transfections and luciferase assays
Twenty-four hours before transfection, HeLa or MDA-
MB-231 cells were seeded in 24-well plates at 8 × 104 cells
per well. Cells were transfected using Lipofectamine 2000
(Invitrogen Life Technologies, Carlsband, CA) and 700 ng
of either pGL3-Basic (control) or the various pGL3-
DCBLD2/ESDN promoter fragments generated and men-
tioned above in presence of 20 ng of pRLTK (Promega,
Madison, WI) to normalize for transfection efficiency fol-
lowing the manufacturer's instructions. In co-transfec-
tion experiments, 250 ng of pSP(RSV)TFAP2A or
pSP(RSV)NN or TFAP2AshRNA2 or pSUPER.retro.puro
vectors were used. Forty-eight hours after transfection
cell extracts were prepared by adding 100 μl of 1 × Passive
Reporter Lysis Buffer (Promega, Madison, WI). The
luciferase activities were measured using the Dual
Luciferase Assay System (Promega, Madison, WI)
according to the manufacturer's instructions. Each trans-
fection was performed in triplicate and repeated three
times. For the statistical analysis a student's t test was
performed: * pv < 0.05; ** pv < 0.01; *** pv < 0.001.
Protein preparation and immunoblotting
Total protein extracts were prepared using a boiling Lae-
mli Buffer containing 0.125 M Tris/HCl, pH 6.8 and 2.5%
SDS. 25 μg of proteins were separated by 12% SDS-PAGE
and electroblotted onto PVDF membranes (Bio-Rad,
Hercules, CA). Membranes were blocked in 5% non-fat
milk-TBS-Tween buffer (137 mM NaCl, 20 mM Tris/HCl,
pH 7.6, 0.1% Tween-20), overnight at 4°C, then incubated
with appropriate antibodies for 1 hour at room tempera-
ture and visualized by enhanced chemiluminescence
(ECL®, Amersham Biosciences, Pisactaway, NJ).
Ingenuity Pathway Analysis Systems
The Ingenuity Pathways Knowledge Base http://
www.ingenuity.com is currently the world's largest data-
base of knowledge on biological networks, with annota-
tions organized by experts. We exploited this database to
define the presence of functional associations within the
genes detected by microarray analysis, to identify
enriched ontological gene classes and to draw simplified
network connections among genes. Each network was
ranked based on "scores" which consider how relevant the
networks are to the genes in our input dataset. Each score
is based on a p-value calculation, which takes in account
the probability that the genes present in a network are
found in it just by chance. Mathematically, the score is
simply the negative exponent of the right-tailed Fisher's
exact test result.
Additional material
Additional file 1 Microarray analysis (Whole Human Genome Agilent 
44 K) was performed on HeLa cells transiently transfected with either 
generic non-silencing (NS) or specific TFAP2A (oligo TFAP2A) siRNA 
oligos. The accession numbers of 494 modulated gene [39] were unambig-
uously converted to ENSEMBL IDs (version 46) and used for our analysis as 
listed here.
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